+33(0)1 42 54 60 64 | contact@welcomeurope.com

Login

EDF – Development of defence medical countermeasures – 2021

The European Defence Fund aims at fostering the competitiveness, efficiency and innovation capacity of the defence technological and industrial base throughout the European Union.

2021-12-09
50 million euro
Close

Appeal framework

Institution European Commission
Sectors Health
Beneficiaries
Regions Developing countries, European Economic Area, European Union
Details
  • Countries eligible for the grant:
    • Member States;
    • The Overseas Countries and Territories (OCTs) linked to the Member States;
    • Associated Countries;
    • The state-members of the European Free Trade Association which are members of the European Economic Area (EEA).

For more information: Click here

Content reserved for subscribers

Register for free to access the content

Free access to all information

Priorities and funded actions

Objectives:

  • To update and/or develop medical countermeasures (MCMs) for the armed forces of EU and – wherever applicable – related civil/health protection to respond to the continuously changing and novel health threats posed by CBRN

Priorities:

  • Provide substantial improvements to the CBRN defence domain for EU armed forces with consistent CBRN medical protections against a large panel of threats currently not covered by drugs produced within EU:
    • to conduct feasibility studies to explore the feasibility of new or improved technologies, products, processes, services and solutions,
    • to design a defence product, tangible or intangible component or technology,
    • to define  the technical specifications on which such design has been developed which may include partial tests for risk reduction in an industrial or representative environment.
  •  Integrating knowledge, testing, qualification, and certification of MCMs.

Among financed actions:

  • Studies;
  • The design of a defence product, tangible or intangible component or technology;
  • Testing: phase I clinical trial with most advanced MCM candidates;
  • Qualification: finalization of a dossier for marketing authorization;
  • Certification: new drug application (NDA) delivered by the regulatory authority (EMA) or early access program.

Additional information:

  • This call for proposals is an open call for proposals.
  • Initial duration of the action: 48 months.

Eligibility:

  • Be a legal person;
  • Be a public or private entity;
  • A consortium composed of at least three entities, established in at least three different EU Member States or associated countries to the programme must be constituted;
  • At least three of those eligible legal entities established in at least two different Member States or associated countries must, during the entire period in which the action is carried out, not be controlled, directly or indirectly, by the same legal entity and must not control each other.
Financement
  • Amount of the grant: 50 million euros.
  • Co-financing rate: up to 90% of the total eligible costs.

 

Test your eligibility

Similar news

6 July 2021

Defence Industry : more than 158 billion euros allocated to 26 new industrial cooperation projects

Lire l'aticle

13 February 2019

Defence: First joint industrial projects coming up

Lire l'aticle